Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Business Wire
Soccer Hall-of-Famer is speaking out for the first time about his private battle with lymphoma and treatment with Breyanzi in honor of World Cancer DayBreyanzi is a personalized, CD19-directed CAR T cell therapy made from a patient’s own T cells and is FDA-approved for five different cancer types, the broadest set of indications of any CD19-directed CAR T cell therapy PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) for the first time. His story details a long and challenging treatment journey that ultimately led him to Breyanzi® (lisocabtagene maraleucel; liso-cel), a personalized CD19-directed CAR T cell therapy made from a patient’s own T cells and administered as a one-time infusion*. Through this collaboration, Kasey aims to empower and inform others navigating their own blood cancer
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Citigroup Inc. from $60.00 to $64.00. They now have a "neutral" rating on the stock.MarketBeat
- Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.MarketBeat
- What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)? [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb (NYSE:BMY) had its "buy" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Bristol Myers Squibb (NYSE:BMY) had its "outperform" rating reaffirmed by analysts at Wells Fargo & Company.MarketBeat
BMY
Earnings
- 2/6/26 - Beat
BMY
Sec Filings
- 2/5/26 - Form 8-K
- 2/3/26 - Form 4
- 2/3/26 - Form 4
- BMY's page on the SEC website